

Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'

We read with great interest the article by Abtahi *et al*,¹ which reported that concomitant use of oral glucocorticoids (GCs) and proton pump inhibitors (PPIs) is associated with a positive risk (1.6-fold) of osteoporotic fractures compared with their non-use in patients with rheumatoid arthritis (RA). In addition, this risk was significantly higher when compared with the single use of GCs or PPIs. Increased fracture risk associated with concomitant GC and PPI use was observed for fractures of the hip, clinical vertebrae, pelvis and ribs, but not for those of the humerus or forearm. Although the findings of this study are relevant to clinicians, some issues remain unaddressed in this regard. Therefore, we attempted to explore these grey areas.

First, there is a need to examine why the Disease Activity Score 28 erythrocyte sedimentation rate (DAS28-ESR) or DAS28-C reactive protein (CRP) was employed in the clinical evaluation.^{2,3} The ability to assess the severity of RA disease and the changes over time in a standard, reliable, and valid manner is essential to evaluate the need for and response to healthcare interventions.^{2,3} Standard assessments of severity have increasingly been devised to focus on RA diseases, so as to respond particularly to the changes in an individual's clinical status. Many reports recommend the use of DAS28-ESR >5.1 or DAS28-CRP >4.6 to define high disease activity, since these cut-off points have been previously validated.⁴ Moreover, this will enable more accurate measurement of disease activity when DAS28-ESR and DAS28-CRP are used. Patients with higher disease activity may have an increased risk of osteoporotic fracture and be more prone to concomitant use of oral GCs and PPIs.^{5,6} Otherwise, a stable clinical status (lower disease activity) may not have led to the use of GCs or PPIs, as well as lower osteoporotic fracture rates. Thus, the observed associations of the concomitant use of oral GCs and PPIs with the risk of osteoporotic fracture reported in this study may be underestimated or overestimated.

Second, postmenopausal osteoporosis is the most common osteoporosis that occurs in women, which subsequently resulted in osteoporotic fractures, even under slight trauma.⁷ Also, statins are widely used for the treatment of hyperlipidaemia and recent in vitro and animal data suggest that statins promote bone formation and increase bone strength.^{8,9} Numerous observational studies have demonstrated that the use of statins is associated with lower risk of osteoporotic fractures.^{10,11} However, postmenopausal status and statins use were not described in the baseline characteristics of these four groups. Therefore, there may be a limited possibility of drawing accurate or reliable conclusions.

Third, this study enrolled 33 369 patients with RA initially, but only 12 351 (37%) patients who met the inclusion criteria were used to further analysis. The patients having a definite RA diagnosis, based on Muller's algorithm, were excluded. We suggested that patients having a definite RA diagnosis based on Muller's algorithm should also be included as a comparison group and that time-dependent Cox proportional-hazard models should also be used to investigate the risk of osteoporotic fracture. Therefore, selection bias may be excluded in this study.

In conclusion, although we share some concerns about this article with Abtahi *et al*, we compliment the authors for their commendable work and hope that this study would benefit the readers.

Tsung-Kun Lin,^{1,2} Lung-Fa Pan,^{3,4} Gwo-Ping Jong^{5,6}

¹Department of Pharmacy, Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan

²School of Pharmacy, National Defense Medical Center, Taipei, Taiwan

³Graduate Institute of Radiological Science, Central Taiwan University of Sciences and Technology, Taichung, Taiwan

⁴Department of Cardiology, Taichung Armed Forces General Hospital, Taichung, Taiwan

⁵Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan

⁶Department of Medicine, Chung Shan Medical University, Taichung, Taiwan

Correspondence to Dr Gwo-Ping Jong, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan; cgp8009@yahoo.com.tw

Handling editor Josef Smolen

Acknowledgements We thank Chung Shan Medical University Hospital for expert technical assistance.

Contributors All authors reviewed the draft and approved the submission of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

T-KL and L-FP contributed equally.



To cite Lin T-K, Pan L-F, Jong G-P. *Ann Rheum Dis* 2023;**82**:e141.

Received 29 March 2021

Accepted 30 March 2021

Published Online First 26 May 2021



► <http://dx.doi.org/10.1136/annrheumdis-2021-220477>

Ann Rheum Dis 2023;**82**:e141. doi:10.1136/annrheumdis-2021-220453

ORCID iD

Gwo-Ping Jong <http://orcid.org/0000-0002-7786-5497>

REFERENCES

- 1 Abtahi S, Driessen JHM, Burden AM, *et al*. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis* 2021;**80**:423–31.
- 2 Prevoo ML, van 't Hof MA, Kuper HH, *et al*. Modified disease activity scores that include twenty-eight-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;**38**:44–8.
- 3 Wells G, Becker J-C, Teng J, *et al*. Validation of the 28-joint disease activity score (DAS28) and European League against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis* 2009;**68**:954–60.
- 4 Fleischmann RM, van der Heijde D, Gardiner PV, *et al*. DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. *RMD Open* 2017;**3**:e000382.
- 5 Raterman HG, Lems WF. Pharmacological management of osteoporosis in rheumatoid arthritis patients: a review of the literature and practical guide. *Drugs Aging* 2019;**36**:1061–72.
- 6 Ozen G, Pedro S, Wolfe F, *et al*. Medications associated with fracture risk in patients with rheumatoid arthritis. *Ann Rheum Dis* 2019;**78**:1041–7.
- 7 Kanis JA, Cooper C, Rizzoli R, *et al*. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 2019;**30**:3–44.
- 8 An T, Hao J, Sun S, *et al*. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. *Osteoporos Int* 2017;**28**:47–57.
- 9 Lee DSH, Markwardt S, Goeres L, *et al*. Statins and physical activity in older men: the osteoporotic fractures in men study. *JAMA Intern Med* 2014;**174**:1263–70.
- 10 Ward IM, Mortensen EM, Battafarano DF, *et al*. Association of statins and risk of fractures in a military health system: a propensity score-matched analysis. *Ann Pharmacother* 2014;**48**:1406–14.
- 11 Lin T-K, Liou Y-S, Lin C-H, *et al*. High-Potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. *Clin Epidemiol* 2018;**10**:159–65.